Related Experiment Video
Updated: Mar 17, 2026

Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS
Published on: January 23, 2026
Vincristine, Adriamycin and Dexamethasone (VAD) as Primary Therapy in Advanced Multiple Myeloma: A Single Centre
A P Macphail1, A Weaving1, W R Bezwoda1
1a Haematology and Oncology Clinics, Hillbrow and Johannesburg Hospitals, University of the Witwatersrand, Johannesburg, South Africa.
Abstract:
Vincristine, adriamycin and dexamethasone (VAD) combination chemotherapy was used as first line therapy in eleven patients with severe myeloma. Eight patients (73%) responded to VAD, six of them achieved complete remission (55%) with paraprotein concentrations falling to zero after a median of three treatment cycles. Median duration of response was 18.5 months with three patients remaining in CR for > 40 months. Median survival for all patients is greater than 62 months. Both infection (two deaths, both non-responders) and a significant decline in cardiac ejection fraction were encountered although only two patients required treatment for cardiac failure. The VAD regimen appears to be an effective first line treatment for severe myeloma producing prolonged survival and rapid response. Further trials with VAD induction followed by maintenance therapy appear to be justified.
Related Concept Videos
Drugs that Destabilize Microtubules
Treatment Resistant Cancers
Treatment Resistent Cancers
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Venous Thrombosis III: Interprofessional Care